Partnerships

Partnership With Janssen

Janssen Biotech Logo

Janssen Biotech, Inc.

We have a license agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for our bacterial consortia drug candidate for Inflammatory Bowel Diseases VE202.

Academic Collaborations

Academic Collaborations

NYU Langone Medical Center

We have entered into a translational collaboration with the NYU Langone Medical Center focused on developing novel microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.

Stanford University School of Medicine

We have entered into a clinical translational medicine collaboration with Stanford University School of Medicine that focuses on food allergies in children in which we will analyze changes in the gut microbiome as they relate to responses to oral immunotherapies in children with food allergies.

Leiden University Medical Center

We have entered into a clinical translational medicine collaboration with Leiden University Medical Center that focuses on patients with C. ​difficile infection or graft-versus-host disease in which we are generating clinical data from interventional studies of fecal transplantation in C. ​difficile patients, as well as clinical data from patients with graft-versus-host disease.

The Leading Platform for Development of Bacterial Consortia Therapeutics

Our discovery platform enables identification of bacterial consortia with drug-like properties and their manufacture to GMP standards.

How Our Proprietary Discovery Platform Works